Aminoglycosides, ethacrynic acid
May increase auditory toxicity. Avoid coadministration.
Antihypertensive effects may be potentiated. Reduce dose by at least 50% when furosemide is coadministered.
May reduce absorption of furosemide.
May cause additive ototoxicity.
Electrolyte disturbances may predispose to digitalis-induced arrhythmias.
May increase plasma lithium levels and toxicity. Avoid coadministration.
Arterial responsiveness to norepinephrine may be decreased.
May decrease effects of furosemide.
May reduce diuretic effects of furosemide.
Because of competition for renal excretion, patients may experience salicylate toxicity. Salicylates may impair diuretic response in patients with cirrhosis and ascites.
The effects may be potentiated by furosemide.
Natriuretic and antihypertensive effects of furosemide may be decreased; separate the administration times by at least 2 h.
Synergistic effects that may result in profound diuresis and serious electrolyte abnormalities.
The skeletal muscle relaxant effect may be antagonized by furosemide.
Acid solutions including other parenteral medications (eg, labetalol, ciprofloxacin, amrinone, milrinone): do not add to furosemide solution; precipitate forms.